Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan
October 17, 2024 08:15 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design
October 09, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock
September 30, 2024 08:15 ET
|
Windtree Therapeutics
Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias NYHA heart...
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
September 26, 2024 16:05 ET
|
Windtree Therapeutics
New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert Review of cardiogenic shock and other programs, including Windtree’s strategy and planned near-term...
Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
September 25, 2024 08:15 ET
|
Windtree Therapeutics
Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many secondary endpoint assessments Study results to be...
Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock
September 04, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates
August 20, 2024 16:05 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Announces New Additions and Changes to Its Board of Directors
August 14, 2024 16:05 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data
July 25, 2024 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage...
Windtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred Stock
July 22, 2024 16:05 ET
|
Windtree Therapeutics
$12.9 Million Transaction Includes Approximately $3.4 Million of New Fundingand a $9.5 Million Full Cancellation of Outstanding Senior Notesand Extinguishment of Series B Preferred Shares The Company...